Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 2, 1998, Pages 168-176

  Scheuerer, Stefan ^b   Hall, Stephen D ^b   Williams, Kenneth M ^b   Geisslinger, Gerd ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; IBUPROFEN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHIRALITY; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; HYPOLIPEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CLOFIBRATE; HUMANS; IBUPROFEN; MALE; REFERENCE VALUES; STEREOISOMERISM;

EID: 0031690584     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90150-3     Document Type: Article

References (51)

1. Adams, SS, Cliffe, EE, Lessei, B Nicholson, JS. Some biological properties of 2-(4-isobutylphenyl)propionic acid. J Pharm Sci 1967;56:1686.
2. Adams SS, Breslof P, Mason CG. Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (-)-isomer. J Pharm Pharmacol 1976;28:256-7.
3. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids - a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693-704.
4. Caldwell J, Hutt AJ, Fournel-Gigleaux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 1988;37:105-14.
5. Knihinicki RD, Day RO, Graham GG, Williams KM. Stereoselective disposition of ibuprofen and flurbiprofen in rats. Chirality 1990;2:134-40.
6. Wechter WJ, Loughhead DG, Reischer RJ, Van Giessen GJ, Kaiser DG. Enzymatic inversion at saturated carbon: nature and mechanism of inversion of R(-)-p-isobutylhydratropic acid. Biochem Biophys Res Commun 1974;61: 833-7.
7. Wechter WJ. On the mechanism of R-arylpropionic acid class NSAIDs: epimerization in humans and the clinical implications for the use of racemates. J Clin Pharmacol 1994;34:1036-42.
8. Nakamura Y, Yamaguchi T, Takahashi S, Hashimoto S, Iwatani K, Nakagawa Y. Optical isomerization mechanism of R(-)-hydratropic acid derivatives. J Pharmacobio-Dyn 1981;4:S1.
9. Brugger R, Garcia Alia B, Reichel C, Waibel R, Menzel S, Brune K, et al. Isolation and characterization of rat liver microsomal R-ibuprofenoyl-CoA synthetase. Biochem Pharmacol 1996;52:1007-13.
10. Tracey TS, Wirthwein DP, Hall SD. Metabolic chiral inversion of (R)-ibuprofen: formation of ibuprofenylcoenzyme A. Drug Metab Dispos 1993;21:114-20.
11. Chen CS, Chen T, Shieh WS. Metabolic stereoisomeric inversion of 2-arylpropionic acids: on the mechanism of ibuprofen epimerization in rats. Biochim Biophys Acta 1990;1033:1-6.
12. Knights KM, Drew R, Meffin PJ. Enantiospecific formation of fenoprofen coenzyme A thioester in vitro. Biochem Pharmacol 1988;37:3539-42.
13. Knights KM, Talbot UM, Baillie TA. Evidence of multiple forms of rat liver microsomal coenzyme A ligase catalysing the formation of 2-arylpropionyl-coenzyme A thioester. Biochem Pharmacol 1992;44:2415-7.
14. Illingworth DR. Lipid lowering drugs: an overview of indications and optimum therapeutic use. Drugs 1987; 33:259-79.
15. Dujovne CA, Harris WS. The pharmacological treatment of dyslipidemia. Annu Rev Pharmacol Toxicol 1989; 29:265-88.
16. Monk JP, Todd PA. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs 1987;33:539-76.
17. Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs 1988;36:314-39.
18. Schoonjans K, Staels B, Grimaldi P, Auwerx J. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur J Biochem 1993;216:615-22.
19. Svensson LT, Wilcke M, Alexson SEH. Peroxisome proliferators differentially regulate long-chain acyl-CoA thioesterases in rat liver. Eur J Biochem 1995;230:813-20.
20. Krisans SK, Mortensen RM, Lazarow PB. Acyl-CoA synthetase in rat liver peroxisomes. J Biol Chem 1980;255: 9599-605.
21. Mentlein R, Lembke B, Vik H, Berge RK. Different induction of microsomal carboxylesterases, palmitoylCoA hydrolases and peroxisomal β-oxidation by clofibric acid. Biochem Pharmacol 1986;35:2727-30.
22. Skrede S, Halvorsen O. Increased biosynthesis of CoA in the liver of rats treated with clofibrate. Eur J Biochem 1979;98:223-9.
23. Knights KM, Addinnall TF, Roberts BJ. Enhanced chiral inversion of R-ibuprofen in liver from rats treated with clofibric acid. Biochem Pharmacol 1991;41:1775-7.
24. Roy-De Vos M, Mayer JM, Etter JC, Testa B. Clofibric acid increases the unidirectional chiral inversion of ibuprofen in rat liver preparations. Xenobiotica 1996;26: 571-82.
25. Baillie TA, Adams WJ, Kaiser DG, Olanoff LS, Halstead GW, Harpootlian H, et al. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J Pharmacol Exp Ther 1989;249:517-23.
26. Rudy AC, Knight PM, Brater DC, Hall SD. Stereoselective metabolism of ibuprofen in humans: administration of R-, S-, and racemic ibuprofen. J Pharmacol Exp Ther 1991;259:1133-9.
27. Scheuerer S, Williams KM, Brugger R, McLachlan AJ, Brune K, Day RO, et al. Effect of clofibrate on the chiral disposition of ibuprofen in rats. J Pharmacol Exp Ther 1998;284:1132-8.
28. Rudy AC, Knight PM, Brater DC, Hall SD. Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment. J Pharmacol Exp Ther 1995;273:88-93.
29. Heinzel G, Woloszczak R, Thomann P. Topfit 2.0. Pharmacokinetic and pharmacodynamic data analysis system. Stuttgart: Gustav Fischer; 1993.
30. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed. Philadelphia: Lea & Febiger, 1989. p. 347-75.
31. Ariens EJ, Wuis EW, Veringa EJ. Stereoselectivity of bioactive xenobiotics: a pre-pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochem Pharmacol 1988;37:9-18.
32. Williams KM, Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985;30:333-54.
33. Brocks DR, Jamali F. Stereochemical aspects of pharmacotherapy. Pharmacotherapy 1995;15:561-4.
34. Sundseth SS, Waxman DJ. Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydrolases: male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. J Biol Chem 1992;267:3915-21.
35. Sharma R, Lake BG, Foster J, Gibson GG. Microsomal cytochrome P-450 induction and peroxisome proliferation by hypolipidaemic agents in rat liver. Biochem Pharmacol 1988;37:1193-201.
36. Milton M, Elcombe CR, Gibson GG. On the mechanism of induction of microsomal cytochrome P450IVA1 and peroxisome proliferation in rat liver by clofibrate. Biochem Pharmacol 1990;40:2727-32.
37. Swinney DC, Webb AS, Freedman R. A novel rat hepatic clofibrate inducible cytochrome P450 that is not a lauric acid hydroxylase. Biochem Pharmacol 1991;42:2341-9.
38. Mayer JM, Testa B, Roy De Vos M, Audergon C, Etter JC. Interactions between the in vitro metabolism of xenobiotics and fatty acids. The case of ibuprofen and other chiral profens. Arch Toxicol Suppl 1995;17:499-513.
39. Mayer JM, Roy De Vos M, Audergon C, Testa B, Etter JC. Interactions of anti-inflammatory 2-arylpropionates (profens) with the metabolism of fatty acids: in vitro studies. Int J Tissue React 1994;16:59-72.
40. Sallustio BC, Meffin PJ, Knights KM. The stereospecific incorporation of fenoprofen into rat hepatocyte and adipocyte triacylglycerols. Biochem Pharmacol 1988;37: 1919-23.
41. Williams KM, Day RO, Knihinicki RD, Duffield A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 1986;35:3403-5.
42. Freneaux E, Fromenty B, Berson A, Labbe G, Degott C, Letteron P, et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids. J Pharmacol Exp Ther 1990;255: 529-37.
43. Zhao B, Geisslinger G, Hall I, Day RO, Williams KM. The effect of the enantiomers of ibuprofen and flurbiprofen on the β-oxidation of palmitate in the rat. Chirality 1992;4:137-41.
44. Fears R. Lipophilic xenobiotic conjugates: the pharmacological and toxicological consequences of the participation of drugs and other foreign compounds as substrates in lipid biosynthesis. Prog Lipid Res 1985;24:177-95.
45. Neupert W, Brugger R, Euchenhofer C, Brune K, Geisslinger G. Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases. Br J Pharmacol 1997;122:487-92.
46. Geisslinger G, Stock KP, Loew D, Bach GL, Brune K. Pharmacokinetics of S(+)- and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis. Eur J Clin Pharmacol 1990;38:493-7.
47. Lee EJD, Williams KM, Day RO, Graham GG, Champion DC. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985;19:669-74.
48. Adams SS, Cliffe EE, Lessei B, Nicholson JS. Some biological properties of 2-(4-isobutylphenyl)propionic acid. J Pharm Sci 1967;56:1686.
49. Sanchez RM, Alegret M, Adzet T, Merlos M, Laguna JC. Differential inhibition of long-chain acyl-CoA hydrolases by hypolipidemic drugs in vitro. Biochem Pharmacol 1992;43:639-43.
50. Hamman MA, Thompson GH, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997;54:33-41.
51. Schenkmann JB, Greim H, editors. Cytochrome P450. Berlin:Springer Verlag; 1993.